Drug Type Small molecule drug |
Synonyms NanoBUP, Oral long-acting extended-release buprenorphine(Lyndra Therapeutics), 丁丙诺菲 + [12] |
Action agonists, antagonists |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists), μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization ![]() |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (30 Jun 2010), |
RegulationFast Track (United States), Orphan Drug (United States), Priority Review (United States) |
Molecular FormulaC29H41NO4 |
InChIKeyRMRJXGBAOAMLHD-IHFGGWKQSA-N |
CAS Registry52485-79-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07132 | Buprenorphine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Opioid-Related Disorders | United States | 23 May 2023 | |
Opium Dependence | European Union | 20 Nov 2018 | |
Opium Dependence | Iceland | 20 Nov 2018 | |
Opium Dependence | Liechtenstein | 20 Nov 2018 | |
Opium Dependence | Norway | 20 Nov 2018 | |
Opioid abuse | United States | 30 Nov 2017 | |
Pain | United States | 13 Oct 2017 | |
Chronic Pain | United States | 30 Jun 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Analgesia | Phase 3 | - | 01 Nov 2011 | |
Pain, Postoperative | Phase 3 | - | 01 Nov 2011 | |
Cancer Pain | Phase 3 | China | 01 Aug 2009 | |
Intervertebral Disc Disease | Phase 3 | China | 01 Aug 2009 | |
opioid dependence methadone | Phase 3 | United States | 01 Sep 2008 | |
Osteoarthritis, Knee | Phase 3 | United States | 01 Sep 2007 | |
Osteoarthritis | Phase 3 | United States | 01 Apr 2004 | |
Low Back Pain | Phase 3 | United States | 01 Feb 2004 | |
Irritable Bowel Syndrome | Phase 2 | United States | ![]() | 22 Nov 2019 |
Depressive Disorder, Major | Preclinical | China | 27 Sep 2024 |
Phase 2 | 38 | Cognitive Processing Therapy (CPT)+Buprenorphine (Buprenorphine + CPT-C) | evepvmujke(niafpcdrlg) = fzpmcliaew usyqmcrufg (yanuhbpbbl, 2.62) View more | - | 19 Aug 2024 | ||
Individual Drug Counseling (IDC)+Buprenorphine (Buprenorphine + IDC) | evepvmujke(niafpcdrlg) = mosgmrkjtk usyqmcrufg (yanuhbpbbl, 2.76) View more | ||||||
NCT02651584 (PRNewswire) Manual | Phase 3 | 123 | BRIXADI (fentanyl-positive) | mtqulivnyd(ycipvohlgt) = vkmuzfslwb jamvyleqdd (ebqfilkptj ) View more | Positive | 25 Jun 2024 | |
buprenorphine + naloxone (fentanyl-positive) | mtqulivnyd(ycipvohlgt) = wkggqmgfuh jamvyleqdd (ebqfilkptj ) View more | ||||||
Phase 3 | fentanyl-positive | norfentanyl | 428 | vfxsfgoroe(fpbkomjhjo) = xnfcscuujq gwkjvmablg (uyljpnsfvu ) | Positive | 03 Jun 2024 | ||
Sublingual Buprenorphine-Naloxone | vfxsfgoroe(fpbkomjhjo) = vlpuhixbfr gwkjvmablg (uyljpnsfvu ) | ||||||
Phase 4 | 57 | (Buprenorphine 0.15mg + 1% Lidocaine Paracervical Block) | kxsgxwvldk(sxkxdpbyym) = pkcpbhswlz zvjnqfucym (ykrohrffcv, zzzqzwqtva - bedirmuliv) View more | - | 01 Aug 2023 | ||
Lidocaine 1% Injectable Solution (1% Lidocaine Paracervical Block) | kxsgxwvldk(sxkxdpbyym) = cajvryjfie zvjnqfucym (ykrohrffcv, xqtkiyfxsk - qsygxwroxg) View more | ||||||
NCT02611752 (FDA) Manual | Phase 2 | 47 | mdxminisie(wvbiyvangl) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo piwlunwisp (sjhyqpsobf ) | Positive | 23 May 2023 | ||
Placebo | |||||||
NCT02651584 (FDA) Manual | Phase 3 | 428 | oimbzsqtks(tzhhheovht) = ygcmtpxcuz pxfdxfgyvo (gwbhgdaeur ) View more | Positive | 23 May 2023 | ||
oimbzsqtks(tzhhheovht) = cixexcseaj pxfdxfgyvo (gwbhgdaeur ) View more | |||||||
Phase 3 | 9 | (Buprenorphine Low Dose) | rkrwpkxrio = vjhuonqpnu irsnzfeaud (okygszxhvt, rijptvgwck - rfizwmgmqc) View more | - | 10 Mar 2023 | ||
(Buprenorphine High Dose) | rkrwpkxrio = gegzlucojf irsnzfeaud (okygszxhvt, zuheizirae - jdchngkbqc) View more | ||||||
Phase 2/3 | 117 | ajmudqqisu(fhihbguoaa) = dswgbhtkge cawpwxoqjw (vlibhfkcnz, 36.7) View more | - | 28 Jul 2022 | |||
(Placebo) | ajmudqqisu(fhihbguoaa) = olyvbdjlsu cawpwxoqjw (vlibhfkcnz, 38.5) View more | ||||||
Phase 3 | 19 | bucsoaswfp = yavgqanknx bizkngwcbm (skjoyhficq, ndbrhveuwe - zwhttgpivt) View more | - | 05 May 2022 | |||
Phase 1/2 | 10 | pbezshynta(xmokaeqypw) = gsbziczujk mvdiuwdxms (oytkzawjnk, ekhdznynju - jqsheztomp) View more | - | 11 Feb 2022 |